论文部分内容阅读
目的探讨CD10、Survivin在弥漫大B细胞淋巴瘤(DLBCL)组织中的表达及其与临床特征、疗效、生存率的关系。方法 DLBCL石蜡标本53例,利用组织芯片免疫组化检测CD10、Survivin的表达情况,并进行临床预后分析。结果 (1)CD10的表达与性别、年龄、B症状、血清LDH水平、结外浸润无相关性,与临床分期有明显相关性。Survivin的表达与此均无相关性。(2)CD10高表达组完全缓解率明显高于低表达组。Survivin高表达组与低表达组差异无统计学意义。(3)CD10低表达患者的生存期明显低于高表达者,Survivin阳性患者的生存率明显低于阴性者。结论 CD10与Survivin可作为DLBCL的疗效和预后指标。
Objective To investigate the expression of CD10 and Survivin in diffuse large B cell lymphoma (DLBCL) and its relationship with clinical features, efficacy and survival rate. Methods Fifty-three cases of DLBCL paraffin specimens were examined for the expression of CD10 and Survivin by tissue microarray immunohistochemistry and clinical prognosis analysis. Results (1) The expression of CD10 had no correlation with gender, age, B symptoms, serum LDH level and extranodal invasion, and had significant correlation with clinical stage. The expression of Survivin had no correlation with this. (2) The complete response rate of CD10 overexpression group was significantly higher than that of low expression group. Survivin high expression group and low expression group difference was not statistically significant. (3) The survival of patients with CD10 low expression was significantly lower than those with high expression, Survivin positive patients survival rate was significantly lower than negative. Conclusion CD10 and Survivin can be used as DLBCL efficacy and prognostic indicators.